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Oestrogen receptor beta isoform
expression in sporadic colorectal cancer,
familial adenomatous polyposis and
progressive stages of colorectal cancer
Paulo Roberto Stevanato Filho1,5*, Samuel Aguiar Júnior1, Maria Dirlei Begnami2, Hellen Kuasne3,4,
Ranyell Matheus Spencer1, Wilson Toshihiko Nakagawa1, Tiago Santoro Bezerra1, Bruna Catin Kupper1,
Renata Maymi Takahashi1, Mateus Barros Filho3, Silvia Regina Rogatto3,4† and Ademar Lopes1†
Abstract
Background: Among the sex hormones, oestrogen may play a role in colorectal cancer, particularly in conjunction
with oestrogen receptor-β (ERβ). The expression of ERβ isoform variants and their correlations with familial
adenomatous polyposis (FAP) syndrome and sporadic colorectal carcinomas are poorly described.
Methods: This study aimed to investigate the expression levels of the ERβ1, ERβ2, ERβ4 and ERβ5 isoform variants
using quantitative RT-PCR (921 analyses) in FAP, normal mucosa, adenomatous polyps and sporadic colorectal
carcinomas.
Results: Decreased expression of ERβ isoforms was identified in sporadic polyps and in sporadic colorectal cancer
as well as in polyps from FAP syndrome patients compared with normal tissues (p < 0.001). In FAP patients, ERβ1
and ERβ5 isoforms showed significant down-expression in polyps (p < 0.001) compared with matched normal
tissues. However, no differences were observed when sporadic colorectal carcinomas were compared to normal
mucosa tissues. These findings suggest an association of the ERβ isoform variants in individuals affected by
germline mutations of the APC gene. Progressively decreased expression of ERβ was found in polyps at early stages
of low-grade dysplasia, followed by T1-T2 and T3-T4 tumours (p < 0.05). In sporadic colorectal cancer, the loss of
expression was an independent predictor of recurrence, and ERβ1 and ERβ5 expression levels were associated with
better disease-free survival (p = 0.002).
Conclusion: These findings may provide a better understanding of oestrogens and their potential preventive and
therapeutic effects on sporadic colorectal cancer and cancers associated with FAP syndrome.
Keywords: Colorectal cancer, ERβ isoforms, Oestrogen receptor, Familial adenomatous polyposis, Hormone
receptors
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Background
Colorectal cancer (CRC), the second and third most com-
monly diagnosed cancer in women and men, respectively,
presents a variable geographical incidence that has been
attributed to differences in diet and environmental expos-
ure [1]. These variations occur in conjunction with a
genetically determined background of susceptibility. The
incidence of CRC is substantially higher in men and
women greater than 50 years of age, although the basis for
this difference is unknown. Sex steroids have been consid-
ered a contributing factor because high parity, early age at
first pregnancy, oral contraceptive use and oestrogen re-
placement therapy are associated with decreased risk of
CRC [2–5]. In addition, younger women (<45 years of
age) with CRC have better overall survival than men of
the same age [6].
Familial adenomatous polyposis syndrome (FAP), a
precancerous colorectal condition, is an inherited disease
caused by a germline mutation in the adenomatous
polyposis coli (APC) gene [7]. In FAP, many neoplastic
lesions of different stages are typically found within the
same individual, thus providing a better understanding
of the adenoma-carcinoma progression. The fact that
these polyps appear in the second decade of life (i.e.,
during puberty) and show increased size and number
during adolescence (i.e., at the peak of production) also
suggests that sex steroids may act as a cofactor in the
development of colorectal polyps and in carcinogenesis
linked to FAP [8].
Evidence from several studies suggests that among the
sex hormones, oestrogen may play a role in colorectal
cancer, particularly through oestrogen receptor-β (ERβ)
[9–13]. However, since the discovery of this receptor in
1996 [14], research efforts have been focused on defining
its biological function, which remains poorly understood.
Several alternative splicing isoforms of the oestrogen re-
ceptor beta gene (ESR2) occur (transcript variants a, b,
d, f, g, h, i, k, l; ERβ isoforms 1–5), and these isoforms
have been detected in both normal and malignant cells
[15–18]. The expression of ESR2 splicing variants in
colon cancer cells was first reported in 2001 [19]. To
our knowledge, this is the first study in which the ex-
pression levels of ESR2 variants in FAP, adenomatous
polyps and sporadic colorectal carcinomas have been
evaluated and compared with normal mucosa, tumour
stage and prognosis data. The goal of this study was to
provide a better understanding of oestrogens and their
potential effects on sporadic and hereditary colorectal
tumours.
Methods
Patients
Fresh frozen tissue samples from 98 patients with sporadic
CRC were retrospectively collected in the Institutional
biobank between the years 2005 and 2016; 48 of the pa-
tients had stage T1/T2 tumours, and 50 had stage T3/T4
tumours. As a reference, paired histologically normal mu-
cosa was obtained from 52 cases. Formalin-fixed, paraffin-
embedded (FFPE) tissue samples were obtained from 52
sporadic polyps. In addition, 64 FFPE polyps and 41 FFPE
adjacent normal tissues were obtained from 41 FAP pa-
tients, between the years 2000 and 2016. All specimens
were submitted to macrodissection and histology confirm-
ation. Tumor samples were composed of at least 70% of
epithelial cells, and normal tissues presented more than
90% of epithelial cells. In total, 307 samples were evalu-
ated, with 921 analyses of three transcripts and their asso-
ciated isoform pairs.
Patients undergoing neoadjuvant treatment and those
with other forms of hereditary CRC or inflammatory
bowel disease were excluded from the study. The Institu-
tional Review Board of the A.C. Camargo Cancer Center,
Sao Paulo, Brazil, approved this study (CEP01453/10).
The histopathological classification of the tumours and the
clinical staging followed the recommendations of the WHO
International Classification of Diseases for Oncology [20]
and the Tumour-Node-Metastasis staging system (TNM)
[21], respectively. The medical records of the patients were
examined to obtain detailed clinical and pathological data.
FAP was diagnosed in individuals with more than 100 aden-
omatous colon polyps or with APCmutations.
The routine follow-up of patients with sporadic colorectal
tumours treated at the institution included quarterly clinic
visits during the first two years, with laboratory tests, assess-
ment of tumour markers, chest X-ray and ultrasound or
abdominal sectional imaging (tomography) performed at al-
ternating visits. These procedures were performed every six
months from the third to the fifth year and annually there-
after. Colonoscopy was performed at the first, third and fifth
years postoperatively. In the event of recurrence, tests were
requested for re-staging and treatment planning. Positron
emission tomography (PET-CT) was performed in cases
considered to have higher risk of metastasis.
The mean follow-up time was 70.1 months, and the
median was 58.6 months (1.67 to 188.7 months). The
FAP patients were carriers of the classic phenotype
(>100 adenomatous polyps) and 53.6% were male with a
median age at syndrome diagnosis of 31 years (19 to
56 year old). The polyps were located in the colon, and
histology analysis showed low-grade dysplasia. Demo-
graphic, clinical and pathological characteristics and
treatment of individuals with sporadic cancer (N = 98)
are summarised in Table 1.
Methods
RNA extraction
Total RNA was extracted from macrodissected fresh fro-
zen tissues and FFPE tissue samples using a QIAsymphony
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RNA Kit (Qiagen) and a RecoverAll Total Nucleic Acid
Isolation Kit (Ambion) according to the manufacturer
instructions. The RNA quantity and quality from tissue
samples (FFPE and fresh frozen) were evaluated using a
NanoDrop ND-1000 Spectrophotometer (v.3.0.1, Lab-
trade). The RNA quality from fresh frozen tissue samples
was also evaluated using the Bioanalyser Agilent RNA
6000 Nano LabChip kit (Agilent 2100 bioanalyser)
(Additional file 1: Table S1).
Selection of the reference genes
The Cancer Genome Atlas (TCGA: level 3 colon tumour
RNA sequencing database) was used to select the refer-
ence genes for RT-qPCR normalisation. The most stable
genes were identified among the 30 potential reference
transcripts (Applied Biosystems TLDA test) using 41
surrounding normal tissues and 285 colon adenocarcin-
omas. A standard deviation (SD) ranking was conducted
for each gene in all samples, and the p-value (unpaired
t-test for unequal variances) was calculated comparing
the normal and tumour samples. The lowest SDs and
highest p-values were ranked; the PUM1, POP4 and
EIF2B1 genes had the highest rankings (lowest variation
between samples and without differences between the
normal and tumour groups). The expression levels of
ESR2 were evaluated by RT-qPCR using the PUM1,
POP4 and EIF2B1 genes as a reference.
Reverse transcription quantitative polymerase chain
reaction (RT-qPCR)
Three pair of primers flanking the ESR1 gene were de-
signed. Primer pair 1 amplifies the transcript variants a,
b, d, f, k and l (ERβ1, ERβ2 and ERβ4 isoforms); primer
pair 2 amplifies transcripts a and g (ERβ1 and ERβ5 iso-
forms), and primer pair 3 amplifies the transcript vari-
ants b, l and k, which are translated into the ERβ2
isoform (Table 2 and Fig. 1). Three endogenous refer-
ences (PUM1, EIF2B1, and POP4) were used in the RT-
qPCR assays (Table 1). The primers were designed using
Primer-Blast (available at http://www.ncbi.nlm.nih.gov/
Table 1 Sample distribution according to the demographic and
clinical variables of individuals with cancer
Variable Category Frequency (%)
N = 98
Gender Male 53 (54.1)
Female 45 (45.9)
Age (years) Variation 41–88
Median 58.6
Mean (Standard Deviation) 65.45 (10.2)
Age range (years) ≤65 52 (53.1)
>65 46 (46.9)
Location Proximal 30 (30.6)
Distal 68 (69.4)
Topography Colon 82 (83.7)
Upper rectal 16 (16.3)
Follow-up time
(months)
Variation (months) 1.7–188.7
Median 58.6
Mean (Standard Deviation) 70.15 (42.3)
Status Living without disease 78 (79.5)
Living with disease 2 (2.04)
Death from other causes 3 (3.06)
Death from disease 15 (15.3)
Recurrence No recurrence 77 (78.5)
Local 1 (1.02)
Liver 13 (13.2)
Lung 4 (4.08)
Peritoneum 3 (3.0)
T Stage T1/T2 48 (48.9)
T3/T4 50 (51.1)
N Stage N0 58 (59.2)
N+ 40 (40.8)
Overall TNM stage S I 39 (39.8)
S II 18 (18.4)
S III 27 (27.6)
S IV 14 (14.3)
Histological grade Well differentiated (G1) 08 (8.2)
Moderately differentiated (G2) 84 (85.7)
Poorly differentiated (G3) 06 (6.3)
Blood embolization No 95 (96.9)
Yes 3 (3.1)
Perineural invasion No 89 (90.8)
Yes 9 (9.20)
Lymphatic embolization No 85 (86.7)
Yes 13 (13.3)
Adjuvant
chemotherapy
No 52 (53.7)
Yes 46 (46.7)
Adjuvant CT scheme No chemotherapy treatment 52 (53.7)
Table 1 Sample distribution according to the demographic and
clinical variables of individuals with cancer (Continued)
Variable Category Frequency (%)
N = 98
FOLFOX 28 (28.5)
5 FU + LV 07 (7.14)
FOLFOX/FOLFIRI +
Bevacizumab
05 (5.10)
FOLFIRI + Cetuximab 1 (1.02)
XELODA/XELOX 5 (5.10)
CT chemotherapy, 5-FU + LV 5-Fluorouracil + Leucovorin (folinic acid), FOLFOX
Leucovorin + Oxaliplatin + Oxaliplatin, FOLFIRI Fluorouracil + Leucovorin +
Irinotecan, XELODA/XELOX Capecitabine combined with Oxaliplatin
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tools/primer-blast/), and Primer 3 was selected based on
the study by Yang et al., 2016 [22].
Total RNA samples were digested with 1 U of DNase I
(amplification grade, Life Technologies) in 10X DNase I
Reaction Buffer. The reactions were performed in a
PTC-100 thermal cycler (Peltier-Effect Cycling - MJ
Research) for 15 min at room temperature; the enzyme
was then inactivated by heating at 70 °C for 10 min. The
cDNA synthesis was performed in a final volume of
20 μL containing 5X first-strand buffer (250 mM Tris–
HCl pH 8.3, 375 mM KCl and 15 mM MgCl2), 10 mM
of each dNTP, 0.5 μg/μL oligo (dT), 0.1 M dithiothreitol
and 200 U of reverse transcriptase (SuperScriptTM
III, Invitrogen). Reverse transcription was performed
at 42 °C for 60 min followed by inactivation at 70 °C
for 15 min. The ABI Prism 7900 Sequence Detection
System automatic thermocycler was used for RT-qPCR
amplification. All reactions were assembled by robotic
pipetting into 384-well plates with QIAgility (Qiagen,
Courtaboeuf, France) in a total volume of 12.5 μL of
Table 2 Sequences and properties of the primers used in the study
Gene Primer 5′ - 3′ Amplicon
length (bp)
Transcript variants Encoded Isoforms
ESR2 F:AATTGACCACCCCGGCAAG 64 a, b, d, f, k and l ERβ1, ERβ2 and ERβ4
Primers 1 R: TTTCCCCTCATCCCTGTCCA
ESR2 F:GGCTAACCTCCTGATGCTCC 57 a and g ERβ1 and ERβ5
Primers 2 R: TCCATGCCCTTGTTACTCGC
ESR2a F:TCTCCTCCCAGCAGCAATCC 154 b, l and k ERβ 2
Primers 3 R:GGTCACTGCTCCATCGTTGC
PUM1 F:CACAGACACCACCTCCTTCC 73
R:CCATTCGTGAGTCCTCCCAG
EIF2B1 F:ACCTGTCTTCATCCTCCCCT 71
R:GCTGCTTTTCGCCTGCATC
POP4 F:TTACCTGCTTTCCCGCTGAG 114
R:GGCTAGGAAGCTACAGCACC
bp: base pairs aThis primer sequence was obtained from ref. [22] F: forward; R: reverse
Fig. 1 Schematic representation of the transcript variants and isoforms of ESR2 gene evaluated in this study. a Three primer pairs were used to amplify
the ESR2 variants. Primer pair 1, in bold, amplifies five ESR2 transcript variants (a, b, d, f, k and l), representing the isoforms ERβ1, ERβ2 and ERβ4. Primer
pair 2, highlighted in dark grey, amplifies the transcript variants a and g (ERβ1 and ERβ5). Primer pair 3, highlighted in light grey, amplifies the variants
b, l and k (ERβ2). b The ESR2 transcript variants are indicated by letters, followed by the correspondent isoforms. Figure modified from UCSC Genome
Browser (https://genome.ucsc.edu). The nomenclature was defined according to NCBI (https://www.ncbi.nlm.nih.gov/nuccore)
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Power SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA), 20 ng of cDNA and 200 nM of
each primer. All samples were analysed in duplicate and
subjected to the following cycling conditions: an initial
temperature of 95 °C for 10 min and 45 cycles of 95 °C for
15 s and 60 °C for 1 min. The amplification quality was
verified by analysing the dissociation curve (specificity) to
discriminate primer-dimers from low levels of transcript
expression. A duplicate of no template control (NTC) was
included in each PCR amplification for each primer pair,
all showing negative signals (Cq = 45 or small dimer amp-
lification detection Cq > 42). The values obtained for all
samples were normalised by determining the ratio of the
gene of interest to the reference gene. The mean Cq
(quantification cycle) was used for normalisation. Samples
with a mean Cq greater than the mean + 1 SD of the
geometric mean of the Cqs of the three reference genes
were excluded (8 fresh frozen and 30 FFPE samples). The
model proposed by Pfaffl [23] was used for data
normalisation.
ESR2 expression in the cancer genome atlas (TCGA)
database of colon cancer
ESR2 expression data in colon carcinomas versus normal
tissues (log2 + 1 reads per million) was assessed from
The Cancer Genome Atlas (TCGA: level 3 RNA sequen-
cing database) (t test). An isoform specific analysis of
ESR2 was implemented using Isoform Expression View
(normal-tumor comparison) of the ISOexpresso tool
(http://wiki.tgilab.org/ISOexpresso/) [22].
Statistical analysis
The findings obtained from five groups of tissues were
compared according to the tissue type: fresh frozen or
FFPE. The variants expression levels of fresh frozen
sporadic colorectal tumours (ST: 98 samples) were com-
pared with normal mucosa (NS: 52 samples). Similarly,
the expression levels of FFPE samples including sporadic
polyps (SP: 52 samples), normal mucosa from FAP pa-
tients (NFAP: 41 samples) and adenomatous polyps from
FAP patients (PFAP: 64 samples) were compared. A
comparison with all groups (NS, ST, SP, NFAP and
PFAP) was also performed, independent of the tumour
type (fresh frozen and FFPE) (Additional file).
Descriptive statistics were used to characterise the
sample. A frequency distribution was used to describe
categorical variables and measures of central tendency
and variability for numerical or continuous variables.
The chi-squared frequency test was used to compare
categorical variables, and Fisher’s exact test was used to
verify associations. Student’s t test (paired and unpaired)
was used to compare continuous variables. Analysis of
variance (ANOVA) was used to compare continuous
variables of multiple groups. The Kaplan-Meier method
was adopted to estimate the overall and disease-free sur-
vival probabilities. The difference between survival
curves of the same variable was evaluated using the log-
rank test. The cut-off for relative gene expression was
determined using the log-rank test (maximally selected
rank statistics in R) [24]. Multivariate analysis was used
to predict the combined effect of independent variables
on survival using the Cox model with proportional risks.
The data were statistically analysed using Statistical Pack-
age for Social Sciences (SPSS) version 20.0 and GraphPad
Prism 5.0 (GraphPad Software Inc., La Jolla, CA). The
significance level for all statistical tests was 5%.
Results
A significant decrease of ESR2 expression levels was ob-
served in polyps and tumours compared to normal mu-
cosa (fresh frozen tissues) or normal tissue from FAP
patients (FFPE samples), regardless of heredity (Fig. 2A).
However, differences in expression levels were found ac-
cording to the group tested and the isoforms.
Primer pair 1: Transcript variants a, b, d, f, k, and l: ERβ1,
ERβ2 and ERβ4 isoforms
The levels of transcript variants a, b, d, f, k, and l, corre-
sponding to the ERβ1, ERβ2 and ERβ4 isoforms, were
significantly lower in sporadic tumours (ST) (p < 0.001;
Mean Diff 3.285; 95% CI 2.780 to 3.791) compared with
normal sporadic mucosa (NS) (fresh tissue) (Fig. 2a).
In FAP syndrome patients, lower expression levels of
ERβ (a) mRNA were found in polyps compared with
paired FAP mucosa samples (p < 0.05; Mean Diff 3.338;
q = 3.854; 95% CI 0.3677 to 6.308). Sporadic polyps (SP)
were also down-expressed when compared to FAP mu-
cosa samples p < 0.05; Mean Diff 3.1; q = 3.883; 95% CI:
0.3621 to 5.839). No difference was observed in sporadic
polyps (SP) versus PFAP (Fig. 2a).
Comparing all FFPE and fresh frozen tissue samples,
no significant differences in mRNA expression levels
were found in sporadic normal mucosa and normal FAP
mucosa. However, invasive polyps and tumours showed
lower ESR2 expression levels compared with normal
mucosa from both, sporadic tumours and FAP patients
(Additonal file 2: Figure S1).
Primer pair 2: Transcript variants a and g: ERβ1 and ERβ5
isoforms
No significant differences were found in the expression
levels of mRNA of ERβ1 and ERβ5 isoforms compared
with normal mucosa (NS) and tumour tissues (ST) from
fresh frozen samples (Fig. 2a). However, in FFPE tissues,
the normal mucosa from FAP syndrome patients showed
high expression levels of ERβ1 and ERβ5 isoforms com-
pared with the sporadic polyps (p < 0.001; Mean Diff
7.568; q = 7.381; 95% CI 4.054 to 11.08) and FAP polyps
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(p < 0.001; Mean Diff 6.4; q = 5.721; 95% CI 2.566 to
10.23) (Fig. 2a).
The analysis of all groups together (Additional file 2:
Figure S1) revealed downexpression levels ERβ1 and β5
isoforms in sporadic tumours compared to normal mu-
cosa of FAP patients (p < 0.001; Mean Diff −5.926;
q = 8.04; 95% CI −8.81 to −3.04). Furthermore, the nor-
mal mucosa of FAP syndrome patients showed a higher
concentration of ERβ1 and ERβ5 isoforms than the other
tissues analysed.
Primer pair 3: Transcript variants b, i and k: ERβ2 isoform
ERβ2 expression levels were significantly lower in
tumour tissues (p < 0.001; Mean Diff 1.718; 95% CI
1.161 to 2.275) than in sporadic normal mucosa (Fresh
frozen tissue). Similarly, for FFPE tissues, lower ERβ2
mRNA expression levels were found in FAP polyps
(p < 0.05; Mean Diff 2.944; q = 4.393; 95% CI 0.6458 to
5.243) and sporadic polyps (p < 0.05; Mean Diff 2.438;
q = 3.945; 95% CI 0.3186 to 4.557) compared with FAP
mucosa.
Considering all groups together (Additional file 2:
Figure S1), sporadic normal mucosa and normal FAP
mucosa showed no significant differences in ERβ2
mRNA levels. No significant differences in ERβ2 expres-
sion between sporadic polyps and tumour tissues were
detected.
ERβ expression according to the cancer genome atlas
(TCGA)
RNA sequencing data from 41 normal mucosa and 285 colon
adenocarcinomas were extracted from the TCGA database. A
significant decrease in ERβ expression level was found in
sporadic tumours (p < 0.001; Mean Diff 0.984 ± 0.146; 95%
CI 0.697 to 1.271) (Fig. 2b). The isoform specific analysis
(http://wiki.tgilab.org/ISOexpresso/) highlighted low expres-
sion levels of the variants d (ERβ4) and b (ERβ2) in tumour
samples (Additional file 3: Figure S2).
ERβ expression according to T stage (TNM)
T3/T4 sporadic tumours presented significantly de-
creased expression levels of ERβ when compared with
Fig. 2 a ESR2 expression levels in sporadic CRC, sporadic polyps and FAP polyps in comparison to normal tissues according to the type of tissue
(fresh frozen tissues: superior graphics or FFPE: inferior graphics). b Comparison of ESR2 expression levels in normal and sporadic colorectal
cancer of TCGA database (log2 + 1 from RNA sequencing read per million values). c The samples were grouped into two T stages using the TNM
classification (T1/T2 vs T3/T4) with relative expression of the ESR2 isoforms. NS = Sporadic normal mucosa; SP = Sporadic polyps; ST = Sporadic
tumour; NFAP = Normal mucosa FAP; PFAP = Polyp FAP; TCGA = The Cancer Genome Atlas level 3) *: p < 0.05; **: p < 0.01; ***: p < 0.001;
(Tukey’s Multiple Comparison Test and Student’s t-test)
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T1/T2 tumours (p = 0.02; Mean Diff 0.87; 95% CI 0.12
to 1.63; Student’s t test). Decreased expression levels
were observed only when Primer 1 was used, which
amplifies a greater number of transcription variants (the
a, b, d, f, k, and l variants, which produce the isoforms
ERβ1, ERβ2 and ERβ4) (Fig. 2c). The comparison of T
stage (TNM) (T1 vs T2 vs T3 vs T4) in the four classes
revealed no significant differences (one-way ANOVA
and Tukey’s post hoc test).
Disease-free survival and overall survival analysis
The time to occurrence of relapse ranged from 4.7 to
36.4 months (median 15.4 months and mean
15.6 months). The probability of recurrence-free survival
was 77.4% for both 5- and 10-year survival. By univariate
analysis, disease-free survival was greater in subjects
≥65 years of age and in those with normal serum carci-
noembryonic antigen levels, T1-T2 tumours, absence of
blood embolization, absence of lymph node or meta-
static invasion, well differentiated tumour histological
grade or Primer 2 (ERβ1 and ERβ5) expression levels
≤ −4.5. (Table 3, Additional file 4: Figure S3). The
multivariate analysis revealed that T and N stage and
ERβ expression levels ≤ −4.5 are independent predic-
tors of disease-free survival (Table 4).
The cumulative probability of overall survival was 83.9%
at 5 years and 77.1% at 10 years. The univariate analysis
revealed greater overall survival in patients with normal
serum carcinoembryonic antigen levels, T1-T2 tumours
and the absence of perineural, lymph node or metastatic
invasion. ERβ expression levels were not statistically sig-
nificant in predicting overall survival (Table 3).
Discussion
The effects of oestrogens on tissue are mediated by
members of the nuclear oestrogen receptor subfamilies
ERα and ERβ. In normal colorectal tissues, ERβ is pre-
dominant and appears to play an important role in the
biological mechanisms of action of sex steroids [25, 26];
its expression decreases at higher Dukes’ stages, which
display little or no ERα expression [9–11, 19]. Despite
being important in the development of breast cancer,
ERα is found in low levels in normal colorectal tissue
[26]. Using different strategies, several studies reported
no differences between the expression levels of ERα
comparing colorectal tumours and normal mucosa
[12, 13, 27–29]. Therefore, the ERβ variant isoforms
may be the key to understand the ERβ signalling in
different tissues [17].
The expression of splicing variants in colon cancer
cells was first reported by Campbell-Thomson et al. in
2001 [19]. In normal human colon tissue, ERβ1, ERβ2
and ERβ5 are expressed, whereas ERβ3 and ERβ4 have
been found only in testicles. In 2005, Wong et al.
reported the expression of ERβ isoforms in colorectal
carcinomas [30]. In that study, the expression levels of
ERβ1 and ERβ2 were completely lost in 22% and 49% of
primary colorectal carcinomas, respectively. In contrast,
a truncated isoform referred to as ERβ5 was found in all
colorectal carcinomas and in tumour cell lines. Despite
the limited number of cases, the authors suggested a
prognostic role of ERβ1 and β2 isoforms.
A few alternative ERβ1 isoforms (ERβ2/ERβcx, ERβ3,
ERβ4 and ERβ5) that result from alternative splicing of the
last receptor-encoding exon have been reported. These
proteins have a truncated domain or are otherwise altered
in the C-terminal region [31]. The C-terminal region of
the ER contains a ligand-binding domain that is involved
in transcription activation, receptor dimerization, nuclear
translocation and interaction of the receptor with tran-
scription co-regulators [32]. Therefore, modifications in
this region can affect the activity and biological function
of the ER. Leung et al. (2006) reported that ERβ2–4-5
isoforms are deficient in intrinsic ligand-dependent trans-
activation activity, making ERβ1 (wild type) the only func-
tional receptor isoform [17]. However, ERβ2–4-5 isoforms
form heterodimers with ERβ1 and may increase ERβ1-
induced transcription activity at physiological oestrogen
concentrations.
In tissues such as prostate, breast and endometrium, a
relationship between oestrogen signalling and the initi-
ation of carcinogenesis, cancer progression and thera-
peutic response have been suggested [16, 33–38].
Oestrogenic action and the quantitative variation in the
proportion of ERβ in different tissues indicate that the
ERβ subtypes have different functions [35, 39]. Although
the specific roles of ERβ subtypes in colorectal cancer
are still uncertain, it is plausible that the varying co-
expression of different isoform groups in normal mu-
cosa, polyps and tumours of the colon, as shown in this
study, can alter carcinogenesis. These findings should be
taken into account in the design of future studies and
screening protocols. In addition, the frequency of screening
examinations should be re-evaluated in subjects who are
undergoing hormone replacement or hormone deprivation
therapy, treatments that are commonly used in breast can-
cer. These patients have a higher risk of developing colo-
rectal cancer, and the hormonal exposure they receive may
be involved in this increased risk. The effect of the use of
hormone replacement therapy in patients with CRC or
FAP syndrome must therefore be carefully evaluated.
The analysis to evaluate ERβ isoforms levels was per-
formed in fresh frozen tissues (sporadic tumours) and in
FFPE samples (sporadic and FAP polyps). One limitation
of our study is the use of FFPE samples, which presents
RNA with lower quality compared to fresh frozen tissue
samples. However, the comparison of the expression
levels of different ERβ isoforms using normal mucosa
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Table 3 Probability of overall survival and disease-free survival at 5 and 10 years according to the demographic, clinical and
pathological variables of sporadic colorectal cancer patients
Variable Overall survival (%) p Disease-free survival (%) p
5-y 10-y – 5-y 10-y
Survival 83.9 77.1 – 77.4 77.4 –
Gender
Male 88.3 79.5 0.220 77.6 77.6 0.952
Female 78.3 71.8 77.3 77.3
Age group (years)
< 65 79.1 72.5 0.248 68.8 68.8 0.039
≥ 65 88.9 82.1 86.7 86.7
Topography
Colon 83.3 74.4 0.430 75.7 75.7 0.403
Upper rectal 86.7 86.7 86.7 86.7
CEA
Normal (<5.0) 90.0 84.0 0.03 83.9 83.9 0.014
Increased (>5.0) 66.8 58.5 59.4 59.4
T stage
T1-T2 95.7 95.7 <0.001 97.9 97.9 <0.001
T3-T4 72.1 40.1 56.7 56.7
N stage
N0 94.9 94.9 <0.001 91.2 91.2 <0.001
N+ 66.6 35.5 55.8 55.8
M stage
M0 90.1 90.1 <0.001 86.1 86.1 <0.001
M+ 49.0 0 28.6 28.6
Histological grade
Well differentiated 87.5 12.5 0.126 87.5 87.5 0.026
Moderately differentiated 53.3 0 78.8 78.2
Poorly differentiated 0 0 40.0 40.0
Blood embolization
No 85.6 78.6 0.002 80.0 80.0 <0.001
Yes 33.3 0 0 0
Lymphatic embolization
No 85.1 60.3 0.151 80.3 80.3 0.079
Yes 76.9 0 58.3 58.3
Perineural invasion
No 84.6 84.6 0.032 79.8 79.8 0.108
Yes 0 0 55.6 55.6
KRAS
Wild 79.8 79.8 0.310 74.2 74.2 0.710
Mutated 61.9 61.9 66.7 66.7
Primer Pair 1- ERβ1, ERβ2 and ERβ4 isoforms*
> −7.2 – – 76.4 76.4 0.301
≤ −7.2 – – 100 100
> −3.2 87.5 87.5 0.361 – –
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(fresh frozen tissue) and normal FAP mucosa (FFPE) re-
vealed decreased ERβ expression in tumour samples and
polyps. This result was confirmed grouping all samples
independently of the tissue type (fresh tissue or FFPE).
To validate the data, RNA-Seq data from 285 colon
adenocarcinomas and 41 non-tumour colon tissue sam-
ples extracted from the TCGA dataset were used. In
agreement with our data, this analysis revealed that
mRNA ERβ expression levels were significantly lower in
tumour tissue than in non-tumorous tissue samples
(p < 0.001; Mean Diff 0.984 ± 0.146; 95% CI 0.697 to
1.271). Nguyen-Vu et al. (2016) using RNA-seq data of
233 colon adenocarcinomas and 21 non-tumor colon tis-
sues from The Cancer Genome Atlas (TCGA) dataset.
The ERβ expression was decreased in the cancerous
state compared to non-cancerous tissues [40].
In our study, ERβ1, ERβ2 and ERβ4 variants (primer
sets 1 and 3) showed downexpression in ST compared to
NS. Similarly, ERβ1, ERβ2, ERβ4 and ERβ5 variants (pri-
mer sets 1, 2 and 3) presented downexpression in FAP
polyps compared with NFAP. These findings were con-
firmed with TCGA dataset results in ERβ2 and ERβ4
performed in sporadic tumours. However, these tran-
scripts demonstrated very low expression by RNA se-
quencing and some variants was not even detected by
TCGA (i.e.: ERβ1 and ERβ5). Although RNA sequencing
is a suitable method to identify and discriminate mRNA
variants, the sensitivity of RT-qPCR is superior, which is
considered a gold standard methodology to evaluate
transcripts [41–43].
Primer pair 2, which amplifies the transcript variants a
and g (encoding ERβ1 and ERβ5) showed the highest ex-
pression levels of ESR2 in normal FAP mucosa (NFAP).
FAP polyps emerge during puberty and increase in num-
ber during adolescence, which is the period of peak
oestrogen production. Based on these findings, it ap-
pears that the transcript variants have the potential to
act as cofactors in the development of polyps and FAP-
related colorectal carcinogenesis. Interesting, comparing
sporadic tumours (ST) with sporadic normal mucosa
(NS), the ERβ1 and ERβ5 levels were not significant.
A primary chemoprevention trial [44] consisting of a
double-blinded, randomised four-year study using sulin-
dac included subjects with APC mutations as well as
phenotypically unaffected subjects. The authors reported
total eradication of the polyps in the placebo group,
which included one patient who received an occasional
administration of oral contraceptives and who had devel-
oped polyps [44]. The patient follow-up comprised
flexible rectosigmoidoscopy every four months for
Table 3 Probability of overall survival and disease-free survival at 5 and 10 years according to the demographic, clinical and
pathological variables of sporadic colorectal cancer patients (Continued)
Variable Overall survival (%) p Disease-free survival (%) p
5-y 10-y – 5-y 10-y
≤ −3.2 82.7 73.5 – –
Primer Pair 2 - ERβ1 and ERβ5 isoforms*
> −4.5 – – 62.5 62.5 0.012
≤ −4.5 – – 85.3 85.3
> −7.6 81.6 81.6 0.118 – –
≤ −7.6 100 100 – –
Primer Pair 3 - ERβ 2 isoform*
> −4.5 – – 76.8 76.8 0.609
≤ −4.5 – – 85.7 85.7
> −3.2 82.4 75.2 0.187 – –
≤ −3.2 100 100 – –
p-value obtained by the log-rank test. Statistically significant p values (p < 0.05) are shown in bold type. *The cut-off for relative gene expression (log2) was
determined using the log-rank test (maximally selected rank statistics in R) [24]
Table 4 Multivariate analysis of the prognostic factors of
disease-free survival in colorectal cancer patients
Variable N HR p 95% CI
T stage (TNM)
T1-T2 47 1.0 0.003 2.88–170.7
T3-T4 51 22.1
N stage (TNM)
N0 59 1.0 0.034 1.09–8.41
N+ 39 3.03
Primer Pair 2 – ERβ1 and ERβ5 isoforms (loss of relative gene expression
(log2)
*
≤ −4.5 65 1.0 0.002 1.69–9.84
> −4.5 33 4.08
*The cutoff for relative gene expression (log2) was determined using the log-
rank test (maximally selected rank statistics in R) [24]
Stevanato Filho et al. BMC Cancer  (2017) 17:754 Page 9 of 12
48 months, and an increased prevalence and recurrence
of polyps was observed after the discontinuation of oral
contraceptives.
Selective oestrogen receptor modulators (SORMs or
SERMs) such as raloxifene and tamoxifen have both
oestrogenic and anti-oestrogenic actions depending on
the tissue type [44–46]. For example, raloxifene is not
only effective in preventing osteoporosis [47] but has
also been shown to be as effective as the SORM arche-
type tamoxifen in preventing breast cancer [48]; how-
ever, it increases the risk of uterine adenocarcinoma
[49]. Despite the widespread clinical application of these
modulators, very little is known about how they may
affect colon cancer. It is important to identify oestrogen
receptor variant subtypes and to determine their relative
expression levels at different stages of tumorigenesis, es-
pecially in different tissues, because specific oestrogen
receptor subtypes can be involved in the specific agonis-
tic or antagonistic actions of oestrogens. The next step
is therefore to determine the correlation between the
predominance of specific isoforms and their interactions
with various forms of oestrogen (isoflavones, SORM and
hormone replacement therapy). The incidence of colo-
rectal cancer is much lower in Asian countries than in
the western world, a fact that may be explained by the
high intake of phyto-oestrogens, such as soy, in Asian
cultures [50]. This intake offers a protective effect
that may be associated with the mediation of ER
binding to genistein, which is the main phyto-
oestrogen in soy and is thought to be a tyrosine kin-
ase inhibitor, a characteristic that may explain some
of its action on the colon [51, 52].
When invasive tumours were analysed individually, no
differences in expression associated with the degree of
tumour differentiation were found. This result likely oc-
curred because the majority (87.8%) of the tumours
studied herein displayed a moderate degree of differenti-
ation. Immunohistochemistry analysis using an ERβ
monoclonal antibody revealed decreased expression in
higher grade or more dedifferentiated tumours [11, 13].
Although the results of a comparison of individual T
stages (T1 vs T2 vs T3 vs T4) were not significant, most
likely due to the limited number of cases at stages T1
and T4, the grouped analysis revealed that larger (T3/
T4) tumours presented decreased ERβ expression levels
compared to T1/T2 tumours. These alterations were
more evident and significant for the primer pair 1, which
amplified the largest number of transcription variants (a,
b, d, f, k and l), representing ERβ1, ERβ2 and ERβ4
isoforms. The amplification with the primers 2 and 3 re-
sulted in a significant reduction of the expression levels
in normal mucosa to very low values during the colorec-
tal carcinogenesis, which may explain the absence of
differences between T1/T2 and T3/T4 tumours. One
plausible explanation is that the primer 1 is more sensi-
tive for the detection of these differences, because con-
tains a group with more homologous variants. The loss
of ERβ expression was significantly different in aden-
omatous polyps with low-grade dysplasia, illustrating
that differences in the expression of these receptors
occur at early stages of carcinogenesis.
Using an expression level threshold of −4.5, we found
that low expression levels of the ERβ1 and ERβ5 iso-
forms (transcript variants a and g: primer pair 2) were
independent factors associated with sporadic colorectal
cancer recurrence (ERβ > −4.5 presented a 4.08-fold
higher risk of relapse (CI 1.69–9.84); p = 0.002).
Paradoxically, this sample set of cases displayed no sig-
nificant difference in loss of normal mucosa ERβ ex-
pression. With respect to polyps and smaller and
larger sporadic tumours, this subgroup was different
in tissues from patients with FAP syndrome; there-
fore, it is plausible that this isoform group may be
correlated with the APC suppressor gene, which is
mutated in FAP syndrome. In contrast, sporadic cases
are often associated with other variables associated
with somatic carcinogenesis.
Cases of FAP cancer were not included in this study,
which was designed to evaluate the prognosis of FAP
tumours, because FAP is a very rare syndrome and
therefore involves a heterogeneous group of patients; as
a result, cases of FAP have been historically treated in
several ways, which may lead to uncertainties in the
prognostic results. Unfortunately, the gold standard for
preventive treatment of colorectal cancer in FAP individ-
uals is still total prophylactic colectomy at a young age,
preferably prior to the malignant transformation of
polyps [7]. Thus, we investigated mRNA expression of
ERβ isoforms in normal mucosa and polyps. Significant
loss was demonstrated in all subgroups of ERβ isoforms
in adenomatous polyps of PAF compared to normal mu-
cosa (p < 0.001).
Recently, an alternative mechanism for oestrogenic
action was described where the G protein-coupled
oestrogen receptor (GPER) mediates the rapid non-
genomic effects of oestrogen, phyto-oestrogen and
xeno-oestrogen [53]. GPER activation may inhibit the
growth of CRC cells, both in vitro and in vivo,
through multiple intracellular signalling pathways. Liu
et al. (2017) showed that GPER expression in tumour
tissue was markedly lower than in corresponding ad-
jacent normal mucosal tissue. Tumours expressing
lower levels of GPER exhibited a significantly lower
survival rate than those with higher GPER expression
levels [54]. The physiological significance of these
rapid effects and their integration with nuclear re-
sponses to oestrogen are important issues that still
need to be further investigated.
Stevanato Filho et al. BMC Cancer  (2017) 17:754 Page 10 of 12
Conclusions
Overall, we demonstrated that the mRNA expression
levels of ERβ isoforms are downregulated in sporadic
colorectal cancer and in FAP individuals. T3/T4 tu-
mours also presented decreased expression of ERβ. Add-
itionally, the expression levels of ERβ1 and ERβ5 were
associated with the probability of disease-free survival.
These differences may inform new clinical studies aimed
at preventative strategies, especially in groups of patients
who are receiving hormone therapy or are under condi-
tions of hormonal deprivation. Although the limitation
of our study was the analysis of the gene expression
levels in a set of FFEP specimens, our data pointed out
that the deregulation of ESR2 isoform variants may be
associated with colorectal cancer progression.
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